| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| TENAX THERAPEUTICS, INC. | Director | Stock Option (right to buy) | 80K | $578K | $7.23 | Nov 17, 2025 | Direct |
| Avalo Therapeutics, Inc. | Director | Restricted Stock Units | 6.33K | $53.6K | $8.46 | Mar 28, 2025 | Direct |
| Avalo Therapeutics, Inc. | Director | Common Stock | 3.17K | $26.8K | $8.46 | Mar 28, 2025 | Direct |
| TENAX THERAPEUTICS, INC. | Director | Common Stock | 1.99K | $15K | $7.52 | Nov 18, 2025 | By Meadowlark Management, LLC |
| BRAINSTORM CELL THERAPEUTICS INC. | Director | Common Stock | 7.18K | $12.7K | $1.77 | Dec 15, 2021 | By Meadowlark Management LLC |
| BRAINSTORM CELL THERAPEUTICS INC. | Director | Common Stock | 6K | $10.6K | $1.77 | Dec 15, 2021 | Direct |
| Avalo Therapeutics, Inc. | Director | Common Stock | 1K | $8.46K | $8.46 | Mar 28, 2025 | By Meadowlark Management, LLC |
| Avalo Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 20.1K | Jun 17, 2025 | Direct | ||
| Actinium Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 0 | Mar 31, 2025 | Direct |